In order to assess the relevance of mTORC2 signaling, we next attempted to analyze the gene expression profile of CD34+ cells derived from CML patients at diagnosis, 24 and 96 h after incubation under hypoxic conditions [35]. The gene discussed is CD34; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.